Pro-regenerative infusible ECM biomaterial for treating acute myocardial infarction
Grant Award Details
Grant Type:
Grant Number:
TRAN1-15291
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$4,353,438
Status:
Active
Grant Application Details
Application Title:
Pro-regenerative infusible ECM biomaterial for treating acute myocardial infarction
Public Abstract:
Translational Candidate
Injectable biomaterial derived from the natural scaffolding of pig hearts
Area of Impact
Improving the quality of life of patients with heart attacks
Mechanism of Action
The proposed mechanism of action is through recruitment of the body's own stem cells and reducing inflammation to heal the heart.
Unmet Medical Need
The prevalence of heart attacks is high yet there are not therapeutics that can adequately prevent heart failure.
Project Objective
Pre-IND meeting
Major Proposed Activities
Injectable biomaterial derived from the natural scaffolding of pig hearts
Area of Impact
Improving the quality of life of patients with heart attacks
Mechanism of Action
The proposed mechanism of action is through recruitment of the body's own stem cells and reducing inflammation to heal the heart.
Unmet Medical Need
The prevalence of heart attacks is high yet there are not therapeutics that can adequately prevent heart failure.
Project Objective
Pre-IND meeting
Major Proposed Activities
- Manufacture product to support nonclinical studies required by FDA
- Nonclinical safety studies
- Clinical trial planning and development
Statement of Benefit to California:
The prevalence of heart attacks in CA is high in adults. The significant reduction in quality of life necessitates the development of new therapies for these patients. Our injectable biomaterial is a cost effective regenerative medicine strategy to improve cardiac function.